Latest Administration News

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Impact Minerals Limited reported a solid cash position of A$3.75 million at quarter-end, supported by a recent equity raise that extends its funding runway to nearly four quarters despite ongoing exploration expenditures.

Xanadu Mines has transitioned operatorship of its flagship Kharmagtai project to Zijin Mining, delivered key feasibility milestones, and is now exploring strategic funding and corporate options amid a solid cash position.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Gas2Grid Limited moves closer to securing a new service contract in the Philippines while appealing a significant legal claim in France, all under the pressure of an impending ASX suspension deadline.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Powerhouse Ventures Limited reports a robust start to 2025, highlighted by strong fund performance, a successful capital raise, and strategic business expansion despite market volatility.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.